Aspen Pharmacare Holdings Stock Price To Sales
Aspen Pharmacare Holdings fundamentals help investors to digest information that contributes to Aspen Pharmacare's financial success or failures. It also enables traders to predict the movement of Aspen Pink Sheet. The fundamental analysis module provides a way to measure Aspen Pharmacare's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Aspen Pharmacare pink sheet.
Aspen |
Aspen Pharmacare Holdings Company Price To Sales Analysis
Aspen Pharmacare's Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Current Aspen Pharmacare Price To Sales | 0.10 X |
Most of Aspen Pharmacare's fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Aspen Pharmacare Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
CompetitionBased on the latest financial disclosure, Aspen Pharmacare Holdings has a Price To Sales of 0.1049 times. This is 99.51% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The price to sales for all United States stocks is 99.08% higher than that of the company.
Aspen Price To Sales Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Aspen Pharmacare's direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Aspen Pharmacare could also be used in its relative valuation, which is a method of valuing Aspen Pharmacare by comparing valuation metrics of similar companies.Aspen Pharmacare is currently under evaluation in price to sales category among its peers.
Aspen Fundamentals
| Return On Equity | 0.095 | |||
| Return On Asset | 0.0499 | |||
| Profit Margin | 0.17 % | |||
| Operating Margin | 0.23 % | |||
| Current Valuation | 4.58 B | |||
| Shares Outstanding | 444.95 M | |||
| Shares Owned By Insiders | 19.32 % | |||
| Shares Owned By Institutions | 60.77 % | |||
| Price To Earning | 11.83 X | |||
| Price To Book | 0.98 X | |||
| Price To Sales | 0.10 X | |||
| Revenue | 38.61 B | |||
| Gross Profit | 18.29 B | |||
| EBITDA | 10.61 B | |||
| Net Income | 6.49 B | |||
| Cash And Equivalents | 7.88 B | |||
| Cash Per Share | 17.25 X | |||
| Total Debt | 105 M | |||
| Debt To Equity | 0.38 % | |||
| Current Ratio | 1.96 X | |||
| Book Value Per Share | 159.44 X | |||
| Cash Flow From Operations | 5.37 B | |||
| Earnings Per Share | 0.80 X | |||
| Number Of Employees | 8.58 K | |||
| Beta | 0.62 | |||
| Market Capitalization | 3.92 B | |||
| Total Asset | 111.38 B | |||
| Retained Earnings | 28.4 B | |||
| Working Capital | 16.1 B | |||
| Current Asset | 37.2 B | |||
| Current Liabilities | 21.1 B | |||
| Z Score | 22.2 | |||
| Annual Yield | 0.02 % | |||
| Net Asset | 111.38 B | |||
| Last Dividend Paid | 3.26 |
Currently Active Assets on Macroaxis
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Other Consideration for investing in Aspen Pink Sheet
If you are still planning to invest in Aspen Pharmacare Holdings check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aspen Pharmacare's history and understand the potential risks before investing.
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |